SeqLL, Inc. (SQL): Price and Financial Metrics


SeqLL, Inc. (SQL): $0.42

0.00 (-0.66%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

SQL Stock Summary

  • SQL has a market capitalization of $4,992,279 -- more than approximately merely 1.16% of US stocks.
  • SEQLL INC's stock had its IPO on August 27, 2021, making it an older stock than just 2.58% of US equities in our set.
  • SQL's price/sales ratio is 43.94; that's higher than the P/S ratio of 96.02% of US stocks.
  • Stocks with similar financial metrics, market capitalization, and price volatility to SEQLL INC are SCWX, TRVN, PTE, SONM, and BAND.
  • To check out SEQLL INC's SEC filings, go to the company's page on browse-edgar?action=getcompany&CIK=0001605888.

SQL Valuation Summary

  • In comparison to the median Healthcare stock, SQL's EV/EBIT ratio is 109.2% lower, now standing at -0.8.
  • Over the past 15 months, SQL's price/earnings ratio has gone up 46.4.

Below are key valuation metrics over time for SQL.

Stock Date P/S P/B P/E EV/EBIT
SQL 2022-12-02 43.9 0.9 -1.2 -0.8
SQL 2022-12-01 43.9 0.9 -1.2 -0.8
SQL 2022-11-30 45.6 0.9 -1.2 -0.9
SQL 2022-11-29 43.9 0.9 -1.2 -0.8
SQL 2022-11-28 45.6 0.9 -1.2 -0.9
SQL 2022-11-25 45.6 0.9 -1.2 -0.9

SQL Stock Price Chart Interactive Chart >

Price chart for SQL

SQL Price/Volume Stats

Current price $0.42 52-week high $2.75
Prev. close $0.42 52-week low $0.37
Day low $0.37 Volume 7,900
Day high $0.43 Avg. volume 51,568
50-day MA $0.56 Dividend yield N/A
200-day MA $0.88 Market Cap 4.99M

SeqLL, Inc. (SQL) Company Bio


SeqLL Inc. operates as a life sciences instrumentation and research services company worldwide. It designs, develops, and manufactures genetic analysis technologies; and offers true single molecule sequencing (tSMS) platform that assists researchers to develop research, diagnostics, and therapeutics applications. The company also provides RNA sequencing services and instruments, which include Direct RNA Sequencing, a genetic testing and mapping service that captures polyadenylated RNA directly without conversion to cDNA; tSMS formalin fixed paraffin embedded (FFPE) service to analyze damaged or fragmented nucleic acids from formalin fixed paraffin embedded samples and other sources; micro RNA sequencing; and custom sequencing, and mapping and testing services, as well as gene expression studies, FFPE RNA Sequencing, biomarker discovery, fusion detection, rare mutation detection, transcriptome profiling, and cap analysis gene expression services. In addition, it offers DNA sequencing services and instruments, such as shotgun DNA sequencing, direct capture sequencing, cell free DNA sequencing, FFPE DNA sequencing, ancient DNA sequencing, and targeted sequencing, as well as microbiome studies, biomarker discovery, and tumor profiling services. Further, the company provides bioinformatics services comprising data processing, biomarkers research, pathway analysis, and gene expression analysis services, as well as undertakes various custom projects. It has a collaboration agreement with Bernstein Laboratory, Ting Laboratory, The Jackson Laboratory for Genomic Medicine, Weizmann Institute of Science, True Bearing Diagnostics, Inc., and Tetracore, Inc. The company serves academic and government institutions, hospitals and medical centers, pharmaceutical and biotechnology companies, and non-profit research organizations. SeqLL Inc. was founded in 2013 and is based in Woburn, Massachusetts.


SQL Latest News Stream


Event/Time News Detail
Loading, please wait...

SQL Latest Social Stream


Loading social stream, please wait...

View Full SQL Social Stream

Latest SQL News From Around the Web

Below are the latest news stories about SEQLL INC that investors may wish to consider to help them evaluate SQL as an investment opportunity.

SeqLL Third Quarter 2022 Earnings: US$0.078 loss per share (vs US$0.089 loss in 3Q 2021)

SeqLL ( NASDAQ:SQL ) Third Quarter 2022 Results Key Financial Results Net loss: US$925.9k (loss widened by 45% from 3Q...

Yahoo | November 11, 2022

SeqLL Provides Third Quarter 2022 Financial Results

BILLERICA, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- SeqLL Inc. (“SeqLL” or the “Company”) (NASDAQ: SQL; SQLLW), a technology company providing life sciences instrumentation and research services aimed at the development of novel scientific assets and intellectual property, today announced its operating and financial results for the third quarter ended September 30, 2022. Third Quarter 2022 Results and Financial Highlights Our revenues during the three months ended September 30, 2022 were $0 as c

Yahoo | November 10, 2022

UPDATE -- SeqLL Announces Peer-Reviewed Publication of Novel Single-Molecule Liquid Biopsy Method in Nature Biotechnology

BILLERICA, Mass., Sept. 13, 2022 (GLOBE NEWSWIRE) -- SeqLL Inc. (“SeqLL” or the “Company”) (NASDAQ: SQL), a technology company providing life sciences instrumentation and research services, today announced a new study demonstrating early cancer detection using SeqLL’s single-molecule technology was published in the peer-reviewed journal Nature Biotechnology. The paper, entitled: “'Multiplexed, single-molecule, epigenetic analysis of plasma-isolated nucleosomes for cancer diagnostics,” applied Se

Yahoo | September 13, 2022

SeqLL Announces Peer-Reviewed Publication of Novel Single-Molecule Liquid Biopsy Method in Nature Biotechnology

BILLERICA, Mass., Sept. 12, 2022 (GLOBE NEWSWIRE) -- SeqLL Inc. (“SeqLL” or the “Company”) (NASDAQ: SQL), a technology company providing life sciences instrumentation and research services, today announced a new study demonstrating early cancer detection using SeqLL’s single-molecule technology was published in the peer-reviewed journal Nature Biotechnology. The paper, entitled: “'Multiplexed, single-molecule, epigenetic analysis of plasma-isolated nucleosomes for cancer diagnostics,” applied Se

Yahoo | September 12, 2022

SeqLL to Present at the H.C. Wainwright 24th Annual Global Conference

BILLERICA, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- SeqLL Inc. (“SeqLL” or the “Company”) (NASDAQ: SQL; SQLLW), a technology company providing life sciences instrumentation and research services for collaborative partnerships, today announced that Daniel Jones, CEO of SeqLL will present a corporate overview and be available for virtual 1x1 meetings at the upcoming H.C. Wainwright 24th Annual Global Conference taking place from September 12-14, 2022. The presentation will be available on demand

Yahoo | September 6, 2022

Read More 'SQL' Stories Here

SQL Price Returns

1-mo -16.00%
3-mo -53.33%
6-mo -41.46%
1-year -83.33%
3-year N/A
5-year N/A
YTD -77.54%
2021 N/A
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.751 seconds.